Jones Trading Reiterates Hold Rating for BioLineRx (NASDAQ:BLRX)

Jones Trading restated their hold rating on shares of BioLineRx (NASDAQ:BLRX) in a report released on Wednesday,Benzinga reports.

A number of other research analysts have also recently issued reports on BLRX. StockNews.com cut shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th. HC Wainwright upped their price target on BioLineRx from $9.00 to $26.00 and gave the stock a “buy” rating in a report on Monday.

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $3.10 on Wednesday. The company’s fifty day moving average is $3.47 and its two-hundred day moving average is $10.57. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The firm has a market capitalization of $10.32 million, a P/E ratio of -0.35 and a beta of 1.39. BioLineRx has a one year low of $2.85 and a one year high of $35.60.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.